IL148057A0 - Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes - Google Patents

Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes

Info

Publication number: IL148057A0
Authority: IL; Israel
Prior art keywords: cgrp; hot flashes; release inhibitors; antagonists; menopausal hot
Prior art date: 1999-08-10

Application number

IL14805700A

Other versions

IL148057A (en

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-10

Filing date

2000-08-05

Publication date

2002-09-12

2000-08-05 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2002-09-12 Publication of IL148057A0 publication Critical patent/IL148057A0/en

2008-04-13 Publication of IL148057A publication Critical patent/IL148057A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL148057A 1999-08-10 2000-08-05 Use of cgrp antagonists for preparing a pharmaceutical composition for treating menopausal hot flashes IL148057A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19937304A DE19937304C2 (en)	1999-08-10	1999-08-10	Use of CGRP antagonists to combat menopausal hot flashes
PCT/EP2000/007613 WO2001010425A2 (en)	1999-08-10	2000-08-05	Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes

Publications (2)

Publication Number	Publication Date
IL148057A0 true IL148057A0 (en)	2002-09-12
IL148057A IL148057A (en)	2008-04-13

Family

ID=7917551

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL148057A IL148057A (en)	1999-08-10	2000-08-05	Use of cgrp antagonists for preparing a pharmaceutical composition for treating menopausal hot flashes

Country Status (32)

Country	Link
EP (1)	EP1207884B1 (en)
JP (1)	JP2003506403A (en)
KR (1)	KR100713573B1 (en)
CN (1)	CN1166361C (en)
AR (1)	AR025078A1 (en)
AT (1)	ATE281168T1 (en)
AU (1)	AU777709B2 (en)
BG (1)	BG65366B1 (en)
BR (1)	BR0013009A (en)
CA (1)	CA2378428C (en)
CZ (1)	CZ300513B6 (en)
DE (2)	DE19937304C2 (en)
EA (1)	EA007531B1 (en)
EE (1)	EE04928B1 (en)
ES (1)	ES2231243T3 (en)
HK (1)	HK1046854B (en)
HR (1)	HRP20020117A2 (en)
HU (1)	HUP0202397A3 (en)
IL (1)	IL148057A (en)
MX (1)	MXPA02001373A (en)
MY (1)	MY129668A (en)
NO (1)	NO20020605L (en)
NZ (1)	NZ517367A (en)
PL (1)	PL198483B1 (en)
PT (1)	PT1207884E (en)
SK (1)	SK285587B6 (en)
TR (1)	TR200200359T2 (en)
TW (1)	TWI285550B (en)
UA (1)	UA73137C2 (en)
WO (1)	WO2001010425A2 (en)
YU (1)	YU8302A (en)
ZA (1)	ZA200200997B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19952147A1 (en)	1999-10-29	2001-05-03	Boehringer Ingelheim Pharma	New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
DE10139410A1 (en) *	2001-08-17	2003-02-27	Boehringer Ingelheim Pharma	Use of BIBN4096 in combination with other anti-migraine drugs for the treatment of migraines
EP1456198A1 (en) *	2001-12-12	2004-09-15	Eli Lilly And Company	Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
DE10206770A1 (en) *	2002-02-19	2003-08-28	Boehringer Ingelheim Pharma	New, stable acid addition salts of the quinazolinone derivative CGRP antagonist BIBN4096, useful for the treatment of migraine, in the form of an inhalable powder
US6900317B2 (en)	2002-02-19	2005-05-31	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (en) *	2002-02-20	2003-08-28	Boehringer Ingelheim Kg	Stable inhalable powder of the calcitonin gene-related peptide antagonist, BIBN4096, useful for treating migraine, in the form of spherical nano-structured particles obtained by spray-drying
DE10227294A1 (en) *	2002-06-19	2004-01-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Preparations for intranasal application of selected amino acid-derived CGRP antagonists and processes for their preparation
DE10250080A1 (en) *	2002-10-25	2004-05-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US7595312B2 (en)	2002-10-25	2009-09-29	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10300973A1 (en) *	2003-01-14	2004-07-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	New carboxylic acids and their esters, medicaments containing these compounds and processes for their preparation
WO2005004869A1 (en) *	2003-07-07	2005-01-20	Boehringer Ingelheim International Gmbh	Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
CA2532064A1 (en) *	2003-07-15	2005-02-03	Merck & Co., Inc.	Hydroxypyridine cgrp receptor antagonists
DE10338399A1 (en) *	2003-08-18	2005-03-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder
DE102004015723A1 (en)	2004-03-29	2005-10-20	Boehringer Ingelheim Pharma	Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US7696195B2 (en)	2004-04-22	2010-04-13	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (en) *	2004-04-22	2005-11-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
DE102004063752A1 (en) *	2004-12-29	2006-07-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of selected CGRP antagonists to combat menopausal hot flashes
DE102004063755A1 (en) *	2004-12-29	2006-07-20	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of CGRP antagonists for the treatment and prevention of hot flushes in patients with prostate cancer
EP1770091A1 (en)	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CGRP-antagonists, process for their preparation as well as their use as medicaments
US7491717B2 (en)	2005-03-23	2009-02-17	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7439237B2 (en)	2005-04-15	2008-10-21	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2132855T3 (en) *	1995-09-07	1999-08-16	Oreal	EXTRACT OF IRIDACEAS AND COMPOSITIONS THAT CONTAIN IT.
US5910482A (en) *	1996-03-19	1999-06-08	Board Of Regents, The University Of Texas System	Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5710024A (en) *	1996-07-23	1998-01-20	Smithkline Beecham Corporation	Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
NZ334543A (en) *	1996-09-10	2000-06-23	Thomae Gmbh Dr K	Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays
DE19911039A1 (en) *	1999-03-12	2000-09-14	Boehringer Ingelheim Pharma	Modified amino acid amides, pharmaceutical compositions containing these compounds and process for their preparation

1999
- 1999-08-10 DE DE19937304A patent/DE19937304C2/en not_active Expired - Fee Related
2000
- 2000-05-08 UA UA2002031932A patent/UA73137C2/en unknown
- 2000-08-05 EP EP00958385A patent/EP1207884B1/en not_active Expired - Lifetime
- 2000-08-05 MX MXPA02001373A patent/MXPA02001373A/en active IP Right Grant
- 2000-08-05 NZ NZ517367A patent/NZ517367A/en unknown
- 2000-08-05 PL PL364049A patent/PL198483B1/en not_active IP Right Cessation
- 2000-08-05 BR BR0013009-5A patent/BR0013009A/en not_active Application Discontinuation
- 2000-08-05 HR HR20020117A patent/HRP20020117A2/en not_active Application Discontinuation
- 2000-08-05 SK SK197-2002A patent/SK285587B6/en unknown
- 2000-08-05 JP JP2001514945A patent/JP2003506403A/en active Pending
- 2000-08-05 TR TR2002/00359T patent/TR200200359T2/en unknown
- 2000-08-05 YU YU8302A patent/YU8302A/en unknown
- 2000-08-05 AT AT00958385T patent/ATE281168T1/en not_active IP Right Cessation
- 2000-08-05 HK HK02108347.1A patent/HK1046854B/en not_active IP Right Cessation
- 2000-08-05 EE EEP200200061A patent/EE04928B1/en not_active IP Right Cessation
- 2000-08-05 ZA ZA200200997A patent/ZA200200997B/en unknown
- 2000-08-05 AU AU69928/00A patent/AU777709B2/en not_active Ceased
- 2000-08-05 ES ES00958385T patent/ES2231243T3/en not_active Expired - Lifetime
- 2000-08-05 KR KR1020027001796A patent/KR100713573B1/en not_active Expired - Fee Related
- 2000-08-05 CA CA002378428A patent/CA2378428C/en not_active Expired - Fee Related
- 2000-08-05 HU HU0202397A patent/HUP0202397A3/en unknown
- 2000-08-05 CN CNB008116156A patent/CN1166361C/en not_active Expired - Fee Related
- 2000-08-05 CZ CZ20020497A patent/CZ300513B6/en not_active IP Right Cessation
- 2000-08-05 IL IL148057A patent/IL148057A/en not_active IP Right Cessation
- 2000-08-05 WO PCT/EP2000/007613 patent/WO2001010425A2/en not_active Ceased
- 2000-08-05 DE DE50008527T patent/DE50008527D1/en not_active Expired - Lifetime
- 2000-08-05 EA EA200200207A patent/EA007531B1/en not_active IP Right Cessation
- 2000-08-05 PT PT00958385T patent/PT1207884E/en unknown
- 2000-08-08 MY MYPI20003601A patent/MY129668A/en unknown
- 2000-08-08 TW TW089115923A patent/TWI285550B/en not_active IP Right Cessation
- 2000-08-09 AR ARP000104098A patent/AR025078A1/en unknown
2002
- 2002-02-06 BG BG106391A patent/BG65366B1/en unknown
- 2002-02-07 NO NO20020605A patent/NO20020605L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
TR200200359T2 (en)	2002-05-21
CZ2002497A3 (en)	2002-06-12
WO2001010425A2 (en)	2001-02-15
AR025078A1 (en)	2002-11-06
DE19937304A1 (en)	2001-03-15
BG106391A (en)	2002-09-30
NO20020605D0 (en)	2002-02-07
PL198483B1 (en)	2008-06-30
BR0013009A (en)	2002-04-30
DE50008527D1 (en)	2004-12-09
UA73137C2 (en)	2005-06-15
HUP0202397A3 (en)	2006-07-28
HRP20020117A2 (en)	2003-10-31
HK1046854A1 (en)	2003-01-30
ES2231243T3 (en)	2005-05-16
EA007531B1 (en)	2006-10-27
HUP0202397A2 (en)	2002-10-28
PT1207884E (en)	2004-12-31
YU8302A (en)	2004-12-31
CA2378428C (en)	2009-10-20
BG65366B1 (en)	2008-04-30
IL148057A (en)	2008-04-13
AU6992800A (en)	2001-03-05
PL364049A1 (en)	2004-12-13
EP1207884A2 (en)	2002-05-29
EE04928B1 (en)	2007-12-17
ATE281168T1 (en)	2004-11-15
KR20020016947A (en)	2002-03-06
SK285587B6 (en)	2007-04-05
CN1166361C (en)	2004-09-15
DE19937304C2 (en)	2003-08-21
MXPA02001373A (en)	2002-07-30
KR100713573B1 (en)	2007-05-02
WO2001010425A3 (en)	2002-02-07
SK1972002A3 (en)	2002-06-04
NO20020605L (en)	2002-02-07
EP1207884B1 (en)	2004-11-03
TWI285550B (en)	2007-08-21
JP2003506403A (en)	2003-02-18
EE200200061A (en)	2003-04-15
MY129668A (en)	2007-04-30
AU777709B2 (en)	2004-10-28
CZ300513B6 (en)	2009-06-03
EA200200207A1 (en)	2002-08-29
NZ517367A (en)	2004-09-24
CA2378428A1 (en)	2001-02-15
HK1046854B (en)	2005-02-25
CN1370069A (en)	2002-09-18
ZA200200997B (en)	2002-10-30

Publication	Publication Date	Title
HUP0202397A3 (en)	2006-07-28	Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes
IL128146A0 (en)	1999-11-30	Tablet with controlled release of alfuzosin hydrochloride
EG24381A (en)	2009-04-05	Tyrosine kinase inhibitors
PL352714A1 (en)	2003-09-08	Diaminothiazoles and their use for inhibiting protein kinases
PL354241A1 (en)	2003-12-29	Kinase inhibitors as therapeutic agents
HUP0200749A3 (en)	2003-03-28	Substituted benzimidazoles and their use as parp inhibitors and process for their preparation
HUP0201393A3 (en)	2002-10-28	Use of xenon for treating neurointoxications
HUP0302544A3 (en)	2012-09-28	Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
HUP0301400A3 (en)	2005-02-28	Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphpnates
HUP0203326A3 (en)	2003-04-28	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
IL156487A0 (en)	2004-01-04	Carbazole derivatives and their use as neuropeptide y5 receptor ligands
HU0900792D0 (en)	2010-03-01	Use of renin-angiotensin inhibitors
IL134013A0 (en)	2001-04-30	Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
IL169183A0 (en)	2009-02-11	Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of patathyroid hormone
AP2003002719A0 (en)	2003-06-30	Use of cox-2 inhibitors for preventing immunodeficiency
AU2790502A (en)	2002-05-21	Pyrimidine derivatives and their use as neuropeptide y receptor ligands
EP1225971A4 (en)	2010-04-07	Controlled release of substances
HUP0104374A3 (en)	2003-03-28	Growth hormone releasing compounds and their antagonists for use for treatment of tumors
IL144603A0 (en)	2002-05-23	Controlled release formulation for treating copd
EP1242699A4 (en)	2004-09-08	Anchoring system for ceramic lining tile
AU2002359792A8 (en)	2003-06-30	Methods and compositions for the inhibition of viral release
SI1207884T1 (en)	2005-02-28	The use of CGRP antagonists and CGRP release inhibitors for the elimination of menopausal hot flushes
GB0119460D0 (en)	2001-10-03	The use of inhibitors of the renin-angiotensin system
SI1268481T1 (en)	2008-06-30	Kinase inhibitors as therapeutic agents
AU2758P (en)	2005-06-02	Adelaide Pink Ozothamnus diosmifolius

Legal Events

Date	Code	Title
2008-11-27	FF	Patent granted
2008-11-27	KB	Patent renewed
2011-04-28	MM9K	Patent not in force due to non-payment of renewal fees